Enrollment completes in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
“The completion of enrollment of Part A of the DeFianCe study is an important milestone for the DKN-01 colorectal cancer development program,” said Cynthia Sirard, M.D., Chief Medical Officer of Leap. “We were very pleased with the enthusiasm of our investigators and patients for participating in Part A, which reflects the unmet medical need of second-line CRC patients and their conviction in the DKN-01 preclinical data and mechanism of action. We look forward to initial data from the study in mid-2023.”
Share:
More News
Paul Hudson, CEO of Sanofi, commented, “The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world’s leading immunology company. This acquisition is fully aligned with our strategic intent to strengthen our existing
Adam Pearson, Chief Strategy Officer, Astellas commented, “Astellas is dedicated to advancing innovative therapies for some of the most challenging-to-treat cancers, such as gastric and pancreatic cancer. XNW27011 is a promising new asset that complements Astellas’ pipeline and enhances our leading position in precision oncology. We look forward to harnessing
“We were honored to present our latest research at the American Academy of Neurology Annual Meeting,” said Jay Hartenbach, President and Chief Operating Officer of Diakonos Oncology. “Glioblastoma remains one of the most aggressive and challenging cancers to treat, and we are committed to advancing novel immunotherapy approaches that have
“Patients with HER2-mutant NSCLC are predominantly women, may be of younger age and non-smokers. The FDA’s decision to grant Priority Review designation to our application for sevabertinib is a significant milestone that validates both the unmet need and the potential for sevabertinib to fulfill that need,” said Christine Roth, Executive
